DNA methylation determination by liquid chromatography–tandem mass spectrometry using novel biosynthetic [U-15N]deoxycytidine and [U-15N]methyldeoxycytidine internal standards by Quinlivan, Eoin P. & Gregory, Jesse F.
Published online 20 August 2008 Nucleic Acids Research, 2008, Vol. 36, No. 18 e119
doi:10.1093/nar/gkn534
DNA methylation determination by liquid
chromatography–tandem mass spectrometry
using novel biosynthetic [U-
15N]deoxycytidine
and [U-
15N]methyldeoxycytidine internal standards
Eoin P. Quinlivan
1,* and Jesse F. Gregory III
2
1Biomedical Mass Spectrometry Laboratory, General Clinical Research Center and
2Food Science and Human
Nutrition Department, University of Florida, Gainesville, FL, USA
Received April 24, 2008; Revised July 24, 2008; Accepted August 4, 2008
ABSTRACT
Methylation of the promoter CpG regions regulates
gene transcription by inhibiting transcription factor
binding. Deoxycytidine methylation may regulate
cell differentiation, while aberrations in the process
may be involved in cancer etiology and the develop-
ment of birth defects (e.g. neural tube defects).
Similarly, nutritional deficiency and certain nutra-
genomic interactions are associated with DNA hypo-
methylation. While LC-MS has been used previously
to measure percentage genomic deoxycytidine
methylation, a lack of a secure source of internal
standards and the need for laborious and time-
consuming DNA digestion protocols constitute
distinct limitations. Here we report a simple and
inexpensive protocol for the biosynthesis of internal
standards from readily available precursors. Using
these biosynthetic stable-isotopic [U-
15N]-labeled
internal standards, coupled with an improved DNA
digestion protocol developed in our lab, we have
developed a low-cost, high-throughput (`500 sam-
ples in 4 days) assay for measuring deoxycytidine
methylation in genomic DNA. Inter- and intraassay
variation for the assay (%RSD, n=6) was _2.5%.
INTRODUCTION
CpG islands are 50-deoxycytidine-deoxyguanosine-30-rich
regions of DNA. In mammalian cells these regions are
initiation sites for DNA transcription (1). Deoxycytidine
methylation (dCyt!MdCyt) of the CpG island plays an
important role in regulating gene transcription by blocking
transcription factor binding. The inhibition of transcrip-
tion factor binding increases exponentially with methyla-
tion density (2) but can be overcome with increased
transcription factor concentrations. Alternatively, the
methylated CpG promoter region can act as an initiation
site for heterochromatin formation (3), which irreversibly
inhibits transcription. By promoting heterochromatin for-
mation, DNA methylation is thought to be a major com-
ponent of epigenetic gene regulation, i.e. inheritance of
information on the basis of gene expression as opposed to
gene sequence (genetics). Examples of epigenetic gene reg-
ulation include autosomal gene inheritance, where one par-
ental copy is silenced (4) and X-chromosome inactivation
inmammals(5).DNAmethylationalsoisthoughttoplaya
role in cell diﬀerentiation, as methylation levels are tissue
speciﬁc (6,7) and change during tissue maturation (6).
CpG hypomethylation has been associated with a
number of carcinoma types including Wilms tumors (8)
(typiﬁed by frequent chromosome 1 and chromosome 16
pericentromeric rearrangements), ovarian epithelial carci-
noma (8) and breast cancer (9). DNA hypomethylation
also may cause chromosomal instability by promoting
stand breakage (10) while the pericentromeric rearrange-
ments observed in the rare genetic disease, immuno-
deﬁciency, centromeric heterochromatin instability and
facial anomalies (ICF), may be due to the associated
hypomethylation of chromosome 1 (11). DNA methyl-
transferase inhibitors cause similar a hypomethylation
and pericentromeric rearrangement of chromosome 1.
Subjects homozygous for the methylenetetrahydrofo-
late reductase (MTHFR) 677C!T polymorphism have
been shown to exhibit (12) global hypomethylation of
DNA, especially when coupled with low plasma folate
(512nmol/l) or red cell folate (51.13nmol/g hemoglobin)
concentrations. It has been suggested that the aberrations
in DNA methylation associated with the MTHFR 677 TT
genotype may explain whythis gene polymorphism is a risk
factor for breast (13), cervical (14) and some colon cancers
(15), and why mothers homozygous for the genotype are
at increased risk (16) of having a child with a neural tube
defect (NTD).
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DNA methylation no ‘gold standard’ exists for its
measurement. Cytosine extension assays (17) are motif
speciﬁc, are unable to distinguish between hemi- and
fully methylated motifs, and exhibit large inter- ( 15%)
and intra ( 4%) assay variability. Methyl-acceptance
assays (18) similarly exhibit large inter- ( 9%) and intra
( 5%) assay variability. For both assays intersample
variability is probably higher, as both assays are depen-
dent on the quality of the DNA sample (e.g. strand
breaks, denatured DNA) which may vary among samples,
and the reproducibility with which the DNA concentra-
tion can be measured (a single sample of homogenous
quality and concentration is typically used to determine
inter- and intraassay variability). Furthermore, both of
these assays are only semiquantitative, as they provide
only a relative measure of dCyt methylation (or rather
a measure of unmethylated dCyt in the CpG motif), not
an absolute measure. This makes comparisons of samples
measured in diﬀerent labs, or measured on diﬀerent days,
diﬃcult.
In contrast, the LC-MS (or LC-MS/MS) methods
provide a quantitative measure of dCyt methylation inde-
pendently of DNA quality. However, most LC-MS meth-
ods lack a readily available and secure source of MdCyt
internal standard. For example, while Friso et al. (19)
used a labeled MdCyt internal standard when developing
their LC-MS method, they needed a custom synthesis. To
compensate for a lack of an internal standard, some devel-
opers of LC-MS methods have used external standards
[intraassay %RSD=4% (20)] or pseudo-internal stan-
dards, e.g. deoxyguanosine [%RSD=1.7–9.2% (21,22)].
In the absence of an internal standard, no correction
can be made for sample recovery during preparation
and for changes in ionization eﬃciency between runs
(e.g. due to ion suppression, detector contamination,
changes in gas pressures, detector saturation or changes
in running buﬀer).
Consequently, we devised a simple and inexpensive pro-
tocol for synthesizing [U-
15N3]-labeled deoxynucleosides
for use as LC-MS/MS internal standards. The starting
materials and biological reagents used in the synthesis are
readily available commercially (ensuring a secure source
of internal standards for future studies), and the biosyn-
thesis can be conducted in a laboratory equipped with
standard biochemical or biological equipment. We report
the use of these stable-isotopic [U-
15N]-labeled deoxynu-
cleosides, speciﬁcally [
15N3]dCyt and [
15N3]MdCyt, as
internal standards in a LC-MS/MS assay for the deter-
mination of percentage DNA methylation (%MdCyt).
EXPERIMENTAL SECTION
Biosynthesis and purification of [U-
15N]-labeled DNA
Cryopreserved Escherichia coli K12 was inoculated into
10-ml growth medium (23) containing 50mM NaCl,
25mM KH2PO5,7 0 mM CaCl, 2.1mM MgSO4,1 0 m M
glucose and 50mM [
15N]NH4Cl (Cambridge Isotopes,
Andover, MA), pH 7.2. The sample was incubated at
378C in a shaking incubator. While in log-phase growth
( 12-h growth) 10 ml of culture was used to inoculate
50ml of fresh [
15N]-labeled growth medium. This second
culture was grown to lag-phase ( 24-h growth), at which
point the bacteria were harvested by centrifuging at 300g
for 10min. Bacterial DNA was extracted using a Bactozol
Kit (Molecular Research Center, Cincinnati, OH) accord-
ing to the manufacturer’s instructions. The Bactazol Kit
includes an RNA hydrolysis step allowing for the selective
precipitation of DNA from cell lysates. The DNA pellet
was washed twice with 75% v/v ethanol and reconstituted
( 50mg/ml) in 10mM Tris–HCl, 50mM NaCl, 1mM
dithiothreitol, 10mM MgCl2 (pH 7.9).
[U-
15N]DNA methylation
To increase [
15N3]MdCyt abundance in the standard the
[U-
15N]DNA was hypermethylated by adding (per 100mg
of DNA) 100U SssI (CpG) methyltransferase (New
England Biochemicals, Ipswich, MA) and 20ml SAM
(32mM), and incubating at 378C for 4h.
Preparation of [U-
15N]internal standard
The hypermethylated [U-
15N]DNA was hydrolyzed to
nucleosides (24) by adding 250U Benzonase (Merck,
Darmstadt, Germany), 300mU phosphdiesterase (Sigma,
St Louis, MO) and 200U alkaline phosphatase (Sigma),
and incubating at 378C for 12h. The percentage unlabeled
deoxynucleoside was determined by analyzing a portion of
the digested internal standard (equivalent to  1mg
[
15N]DNA) by LC-MS/MS. The peak corresponding to
the unlabeled (M+0) and labeled (M+3) deoxynucleo-
sides was integrated. [In the case of the unlabeled
(M+0) peak this was mainly background noise]. The
area of each unlabeled deoxynucleoside peak was
expressed as a percentage of the corresponding M+3
labeled deoxynucleoside peak.
DNA digestion
DNA was quantiﬁed using a PicoGreen kit (Invitrogen,
Carlsbad, CA) according to the manufacturer’s protocol.
Digest Mix (enough for 100 samples) was prepared using
250U Benzonase, 300mU phosphdiesterase, 200U alka-
line phosphatase, 200ml of digested [U-
15N]DNA (equiva-
lent to  10mg DNA) and 0.5ml 10  Buﬀer [100mM
Tris–HCl, 500mM NaCl, 100mM MgCl2 (pH 7.9)], and
made up to 5ml with water. DNA samples (1mg in 50-ml
water) were digested by adding 50ml Digest Mix and incu-
bating at 378C for 6h.
Liquid hromatography–tandem mass spectroscopy
Sample injection was 10ml (equivalent to 100ng DNA).
DNA digests were chromatographed using a 3mm Luna
C18(2) column (50 3mm, Phenomenex, Torrance, CA)
eluted with 5mmol/l ammonium acetate/0.1% (v/v)
acetic acid using a methanol gradient at a ﬂow rate
of 0.5ml/min. The methanol gradient increased linearly
from 4% to 18% over 3.5min. where it was held
for 1.5min, after which it returned to baseline (4%).
There was a 1-min delay before the next injection—not
allowing the column to fully equilibrate improved the
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Samples were analyzed in ESI mode using a triple quad-
rupole mass spectrometer. For the determination of
isotopic nucleosides enrichment scanning was performed
in positive ionization mode using selected reaction
monitoring (SRM) mode, monitoring the mass to charge
(m/z) transitions of dCyt: 228.1!112.0; [
15N3]dCyt:
231.1!115.0; MdCyt: 242.1!126.0; [
15N3]MdCyt
245.1!129.0. Chromatograms were analyzed using the
Xcalibur software package (Thermo; Version 2.0).
Preparation of standardcurves
Stock solutions of dCyt (Sigma) and MdCyt (ChemGenes
Corporation, Wilmington, MA) were prepared in water.
The concentration of the stock solutions was determined
by diluting 1 in 10 with 0.1M HCl and measuring their
absorbance. The molar absorptivity coeﬃcients (“) used
were: dCyt “ = 13400M
–1cm
–1 at 280nm and MdCyt
“=12200M
–1cm
–1 at 286nm (25).
A stock mixture of the two standards was carefully pre-
pared to give an exact known concentration ratio of dCyt
to MdCyt (typically on the order of 12:1). The stock
solution was further diluted to make a working solution.
A standard curve was prepared from the working solution
by serially dilution with water (Figure 1). To 50ml of each
standard dilution was added 50ml of the Digest Mix (con-
taining the [U-
15N] internal standards). Standard curves
were prepared by plotting the analyte/internal standard
ratio (M+0/M+3) against nucleoside concentration.
Determining percentage deoxycytidine methylation
The concentration of dCyt and MdCyt in each sample was
calculated from the standard curves using the analyte/
internal standard ratio (M+0/M+3) by reverse predic-
tion. Percentage dCyt methylation (%MdCyt) was calcu-
lated by dividing the MdCyt concentration by the total
dCyt concentration ([dCyt] + [MdCyt]).
Inter- andintraassay variability
Intraassay variability was determined by running six
replicate DNA samples within the same run. Interassay
variability was determined by running six replicate DNA
samples on 6 consecutive days.
Effectof [U-
15N]DNA concentration on measured
deoxycytidinemethylation
To determine the eﬀect of variations in the volume
(e.g. due to pipetting error) of added [U-
15N]DNA inter-
nal standard had on %MdCyt, 50ml of a stock dCyt
and MdCyt mixture were spiked (in triplicate) with 25,
50 or 75ml of the Digest Mix. Concentrations of dCyt
and MdCyt were determined as described above, as was
%MdCyt.
Preparation ofstock DNA mixtures of varying
percentage DNA methylation
Using a REPLI-g Midi kit (Qiagen, Valencia, CA)
100ng of pooled lymphocyte DNA was ampliﬁed to
 40mg according to the manufacturer’s instructions.
Ampliﬁcation produces an unmethylated end product
that, according to the manufacturer’s literature, is essen-
tially fully double stranded. The ampliﬁed DNA was
divided, and half was methylated using SssI (CpG)
methyltransferase (New England Biochemicals). The
DNA was puriﬁed using a Qiaex II Gel Extraction
Kit (Qiagen). The methylated and unmethylated DNA
was mixed to give a series of samples with known ratios
of methylated to unmethylated DNA. Percentage DNA
methylation for each sample was determined by LC-MS/
MS as described above.
Methyl-acceptance assay
DNA samples showing wide variability in methylation
(as determined by LC-MS/MS) were identiﬁed from a
folate intervention study (26). The relative abundance of
unmethylated cytosines in the CpG motif in these samples
was determined using a modiﬁcation (27) of the Balaghi
and Wagner [
3H]methyl-acceptance assay (28). In brief,
DNA (0.5mg) was incubated with SssI methyltransferase
(New England Biolabs, Beverly, MA) and [
3H]methyl
S-adenosylmethionione (New England Nuclear, Boston)
at 308C for 4h. The DNA was collected on a DE81 ion-
exchange ﬁlter. After washing, to remove unincorporated
0
2
4
6
8
10
12
14
16
18
0.0 0.5 1.0 1.5 2.0
r = 0.9989
0
3
6
9
12
1.5 2.0
r = 0.9999
0
2
4
6
8
10
12
14
0 5 10 15 20 25
r = 0.9865
0
20
40
60
80
0 5 10 15 20 25
(a) (b)
R
a
t
i
o
 
M
d
C
y
t
:
 
[
1
5
N
3
]
M
d
C
y
t
M
d
C
y
t
 
p
e
a
k
 
a
r
e
a
 
(
×
1
0
−
6
)
d
C
y
t
 
p
e
a
k
 
a
r
e
a
 
(
×
1
0
−
6
)
R
a
t
i
o
 
d
C
y
t
:
 
[
1
5
N
3
]
d
C
y
t
[dCyt] (µmol/L) [MdCyt] (µmol/L)
r = 0.9996
1.0 0.5 0.0
Figure 1. Standard curves for (a) deoxycytidine and (b) 5-methyldeoxycytidine, corrected for recovery of their respective [
15N3]-labeled internal
standard. Insets, uncorrected standard curves.
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tillation counter. Each DNA sample was analyzed in
triplicate. Typical inter- and intraassay variability deter-
mined using a pooled lymphocyte DNA sample were 10
and 7%, respectively.
RESULTS AND DISCUSSION
[U-
15N]internal standard
Using only a portion of the [U-
15N]-labeled DNA
extracted from each 50ml E. coli culture, we were able
to produce several milligrams of hypermethylated DNA.
After digesting to deoxynucleosides this produced enough
[U-
15N]-labeled internal standard for several tens-of-thou-
sands of assays. All of the components used are inexpen-
sive and readily available commercially. This biosynthetic
method produced highly enriched [
15N3]dCyt and
[
15N3]MdCyt internal standards containing50.5% of the
unlabeled (M+0) isotopomer. Similarly, the contribution
of unlabeled dCyt and MdCyt standards to the M+3
signal (e.g. due to natural enrichment) was minor (50.1%).
Liquid chromatography–tandem mass spectroscopy
The chromatographic conditions gave good separation of
dCyt and MdCyt (Figure 2). The relatively high speciﬁcity
of the mass transitions employed yielded good signal-
to-noiseratioswithnegligibleappearanceofcontaminating
peaks. [
15N2]Deoxyuridine and [
15N2]thymidine (derived
from the [U-
15N]-labeled DNA) have, respectively,
similar mass transition to [
15N3]dCyt (231.1!115.0)
and [
15N3]MdCyt (245.1!129.0). However, their reten-
tiontime (deoxyuridine=1.59min; thymidine=3.13min)
were suﬃciently dissimilar from dCyt (retention
time=1.20) and MdCyt (retention time=1.94) so as
not to interfere with the analysis. Furthermore, under
normal experimental conditions [
15N2]deoxyuridine was
not present at detectable concentrations.
Standard curves
After adjusting for internal standard recovery (M+0/
M+3), standard curves were linear over the range of
interest (dCyt: 1–100mmol/l; MdCyt: 0.1–10mmol/l;
P 0.999) and over a range at least an order of magnitude
higher and lower.
Inter- andintraassay reproducibility andvariability
The assay exhibited good reproducibility and little
inter- (4.36%; %RSD=2.36%; n=6) and intraassay
(4.33%; %RSD=2.49%; n=6) variability. The impor-
tance of using an internal standard was evident from the
large variability observed for the unadjusted dCyt and
MdCyt peak areas (Table 1). This was particularly evident
for MdCyt determination, where a large decrease in peak
area ( 25%) was observed between the third and subse-
quent samples, resulting in a large variation in peak
area (%RSD 20%). However, as the response of
the [
15N3]MdCyt internal standard was similarly aﬀected
(as would be expected), the %RSD for the corrected
MdCyt peak area (M+0/M+3) was only 2.54%.
Figure 2. LC-MS/MS chromatogram of a typical sample, showing
(a) deoxycytidine, (c) 5-methyldeoxycytidine peak, (b) and (d) their
respective [
15N3]-labeled internal standard peaks.
Table 1. An example of interassay peak area variability observed in the assay, and its correction using recovery of the [
15N3]-labeled
internal standard
Sample
a dCyt peak area MdCyt peak area
Analyte
b [
15N3]
c Ratio
d Analyte
b [
15N3]
c Ratio
d
1 99681858 12915824 7.72 20661241 4261932 4.85
2 96111965 12214937 7.87 20358454 4175934 4.88
3 100721386 13179525 7.64 19816002 4174776 4.75
4 116390992 14718118 7.91 15388665 3056475 5.03
5 109791299 15053509 7.29 13830853 2859798 4.84
6 99047865 13201706 7.50 13496698 2888077 4.67
Mean 103624228 13547270 7.66 17258652 3569499 4.84
%RSD 7.5 8.1 3.0 19.5 19.5 2.54
aSix replicates of a pooled sample were independently digested and analyzed consecutively by LC-MS/MS, as described in the text.
bPeak area of the analyst (M+0).
cPeak area of the [
15N3]-labeled internal standard (M+3).
dRatio of analyte (M+0) to [
15N3]internal standard (M+3).
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concentrations
As expected, the volume of internal standard added to the
sample greatly aﬀected (Table 2) apparent dCyt and
MdCyt concentration. In contrast, %MdCyt values were
independent of the internal standard concentration.
Similarly, when changing the sample DNA concentration
(using 0.5, 1.0 or 1.5 mg) the measured concentrations of
dCyt and MdCyt increased with DNA concentration,
while the %MdCyt was consistent (%RSD=2.3%; data
not shown). Consequently, the amount of internal
standard or sample DNA used in the assay has little
eﬀect on the measured %MdCyt.
Linearity of DNA admix
The REPLI-g ampliﬁed product exhibited little (50.1%)
DNA methylation while the post methylated (with SssI)
DNA had 3.94% DNA methylation. Admixes of the
methylated and unmethylated DNA, containing diﬀerent
ﬁxed ratios of the methylated and unmethylated DNA,
exhibited (Figure 3) good linearity (r=0.9998) when
assayed by LC-MS/MS.
Comparison of LC-MS/MS and [
3H]methyl-acceptance
assayresults
Results from the LC-MS/MS assay and the [
3H]methyl-
acceptance assay are not directly comparable as the
LC-MS/MS assay quantitatively measures the per-
centage of methylated dCyt in the sample, while the
[
3H]methyl-acceptance assay semiquantitatively measures
the number of unmethylated dCyt in the CpG motif
(e.g. the results from both assays are, at best, inversely
proportional). However, within the conﬁnes of the
assay (particularly the [
3H]methyl-acceptance assay) the
two assays showed good agreement with each other
(Table 3), with samples with a relatively low %MdCyt
exhibiting a relatively high methyl-acceptance capacity.
Sample throughput and clinical applications
Using a Repeater Pipetter (Eppendorf) it was possible to
add Digest Mix to each well of a 96-well plate in52min.
In this manner 4500 pre-plated samples (26,29) could
be digested in a single day. These 4500 samples could
then be analyzed LC-MS/MS in 53 days, due to the
short chromatography time for each sample (6min. from
injection to injection).
CONCLUSION
We have devised a simple and inexpensive protocol
for synthesizing [U-
15N3]-labeled deoxynucleoside. Using
these [U-
15N3]internal standards we have devised a
LC-MS/MS protocol for the high-throughput determi-
nation of percentage DNA methylation. The one-step
sample digestion procedure, and ability to prepare
and analyze large numbers of samples (4500 samples)
in a single assay, greatly reduce the risk of sample
error and potentially limits intersample variability.
Furthermore, as this method gives an absolute measure
of DNA methylation (rather than the relative values deter-
mined by the cytosine extension or [
3H]methyl-acceptance
Table 2. The eﬀect of varying the volume of [U-
15N]-internal standard added on the apparent concentrations of deoxycytidine (dCyt) and
5-methyldeoxycytidine (MdCyt), and on apparent percentage deoxycytidine methylation (%MdCyt)
dCyt (mmol/l) MdCyt (mmol/l) %MdCyt
a
Stock 10.93
b 0.93
c 7.81
Digest Mix
d Mean SD
e Accuracy (%) Mean SD
f Accuracy (%) Mean SD Accuracy (%)
25ml 20.83 0.06 190.6 1.79 0.08 192.5 7.91 0.31 101.3
50ml 10.58 0.10 96.8 0.92 0.02 98.9 8.00 0.25 102.4
75ml 6.98 0.04 63.9 0.60 0.01 64.5 7.95 0.17 101.8
aPrecentage MdCyt to total dCyt (MdCyt+dCyt).
bFinal concentration of dCyt if 50ml of Digest mix was used.
cFinal concentration of MdCyt in a ﬁnal volume of 100ml.
dVolume of Digest Mix (containing digested [U-
15N]DNA as internal standard) added to sample (normal amount added to the sample is 50ml).
eMeasured concentration of dCyt, estimated from a standard curve using the M+0/M+3 ratio.
fMeasured concentration of MdCyt, estimated from a standard curve using the M+0/M+3 ratio.
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